drugset / Trial / NCT01108783

A Phase III Efficacy Study of the Symptomatic Treatment of Seasonal Allergic Rhinitis With Bilastine

NCT01108783

Phase 3 Completed 720 enrolled Faes Farma, S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study was to determine the efficacy and tolerability of 20 mg of Bilastine, compared to Desloratadine and placebo for the treatment of Seasonal Allergic Rhinitis.

Timeline

Start
2003-04
Primary completion
2003-08
Completion
2004-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Bilastine Small molecule 20 mg
Comparator Desloratadine Small molecule 5 mg